Evan Seigerman

Boerner gave the criteria (known therapeutic areas, compelling science, financial case) without naming targets, as the analyst pre-conceded.

Cristian detailed dose selection from Phase II, the 20,500-patient study design, and predefined noninferiority margins disclosed at 0.8% to 1.3%.

Adam said competitive data adds conviction in broad pumitamig development. Cited multiple ongoing trials in NSCLC, SCLC, TNBC, MSS CRC, and gastric cancer. Focus on speed to first/second-to-market.

Chris emphasized first/second-to-market positioning learned from Opdivo. Samit highlighted PD-L1 tumor specificity as differentiation vs PD-1/VEGF inhibitors.

Adam noted label change simplifies processes, opens COE capacity, and early customer feedback very positive. Over 15,000 US patients prescribed.

Chris agreed with administration on ex-US pricing differential but emphasized fixing US complexity, 65 cents of every dollar goes to middlemen.

Chris outlined disciplined BD framework: science conviction, strategic fit, financial rigor, and speed of execution as key factors.

Adam highlighted expanding prescriber base, high persistency, duration of therapy, and continued new patient adds each week.

Chris framed the MEVPRO-1 readout around the statistical analysis plan's ~30% benefit bar over standard of care; addressed the success definition directly.

Dave signaled share buybacks moving into greater consideration with improved cash flow visibility from legal wins, but offered no specific timeline or quantum.

Boshoff cited AI embedding across discovery, medical, regulatory, safety, and clinical execution measured by productivity, speed, and cost; Malik gave field force productivity and MROI optimization examples; Alexandre highlighted pre-call planning and advanced targeting; Bourla framed AI as key to taking cost out without affecting activity.

Denton outlined productivity-driven deleveraging from 4x to 2.7x; will continue investing in key pipeline assets and launched products to offset LOEs; share repurchases not near-term priority given balance sheet rebuild needs post-Metsera.

Bourla projected Seagen assets from $2B to $10B by 2030; Boshoff detailed SV Phase III fully recruited faster than expected, PDL1V Phase III for head and neck, and new TOPO1 payload ADCs in Phase I.

Boshoff cited 60% discontinuation rate for current obesity medicines as opportunity; emphasized tolerability, accessibility, and personalized combinations; Baum added commercial differentiation across indications.

Bourla acknowledged strong relationship with Trump from Warp Speed, personal meetings with Kennedy, and expressed cautious optimism that opportunities may outweigh risks.

Charlie: ~$200M non-CF in H1, CASGEVY the bigger contributor; declined to split the H2 balance but confident in $500M+.

Reshma attributed VX-522 failure to inflammatory response to the LNP delivery system. Committed to pursuing nucleic acid therapies for the last 5,000 CF patients but acknowledged delivery remains the key challenge.

Reshma cited ~200,000 US/EU patients, limitations of cycling-on/off therapies, compelling wild-type TACI data from China on MG-ADL scores, and pove's engineered superiority. Phase 2 dose-ranging study at 80mg and 240mg to initiate shortly.

Duncan emphasized that monthly dosing, small volume, and at-home auto-injector significantly reduce patient burden and improve adherence. Combined with mechanism and clinical data, these give pove best-in-class potential.

Reshma cited combination of emerging clinical data from RUBY-3/RUBY-4, treatment landscape analysis, commercial opportunity, and pove's engineered best-in-class properties. Ready for FDA pivotal discussions on gMG.

Stuart cited progress on ATC activations, securing reimbursement globally, and growing center familiarity with the treatment process as drivers of Q1 acceleration expected to continue through 2025.

Stuart expressed confidence in broad access over time but declined to provide specific covered lives expectations or timeline guidance.

Viehbacher built the market case from patient count, IgAN pricing analogue and the 80% Phase 2 resolution rate, but did not specify what data would convince investors.

Alisha explained U.S. Q1 was impacted by Q4 inventory build and 2 fewer buying weeks. Demand on par. U.S. launch now in community phase where majority of patients come from single-script doctors finding older, slower-progressing patients. Robin noted ex-U.S. revenue exceeded U.S. for first time, with continued launches across 35 countries and reimbursement progression.

Chris cited Japan launch running ahead of expectations with evidence of switchbacks. Higher efficacy at therapeutic levels faster. Market research suggests potential sales increase but actual data will tell. Key dynamic is efficacy (SPINRAZA) vs convenience (oral). Europe launch teams excited.

Chris positioned Biogen as always having been an immunology company. Near-term focus on rare immunology and areas overlapping with existing expertise (lupus parallels MS). Longer-term (10 years), broader indications possible. Felzartamab exploring 3 additional non-kidney indications. Vanqua deal exemplifies early-stage portfolio building.

Chris explained subcu helps establish maintenance market by extending treatment life, reduces caregiver burden, and enables treatment in rural settings without infusion centers.

Priya acknowledged the scientific hypothesis but noted prior RCT failures including Novo liraglutide ELAD trial. Emphasized LEQEMBI addresses central pathology and will maintain important role regardless.

Cagnoni named both benchmark sets, chemotherapy response rates and competitor combination data, and claimed potential best-in-class positioning in frontline pancreatic.

Steven outlined three strategies: larger study size, minimum abscess/nodule requirements at entry, and using HiSCR75 as higher bar. Two studies designed to control artificial placebo response rate.

Bill outlined 7 key programs: povo (3 indications), 989, 617F (2x 989 potential), G12D, TGF-beta x PD-1, CDK2, and Niktimvo. Need 2-3 of 7 to hit. Systematically building high-impact oncology portfolio.

Bill framed Rezurock as floor for Niktimvo. Mohamed said capturing 30% of in-play market by year-end could position ahead of analogs, with several hundred million in annual sales by 2028. Bill focused BD on chronic disease management in hem/onc and I&I.

Christiana quantified gap: 20% US revenue growth vs 24% demand growth due to holiday-driven Q4 inventory build normalizing. Matteo expects higher tube utilization driven by subscription growth.

Matteo sized pediatric AD at 10-15% of total AD Opzelura business at peak. On adalimumab head-to-head, Herve deferred decision until Phase 3 data; noted real-world Humira dissatisfaction with rapid drug failure.

Schleifer explicitly limited the answer because negotiations are live, but signaled the original terms need updating to reflect Regeneron's changed scale.

Yancopoulos enthusiastically argued the GLP+Praluent combo would become the preferred GLP by offering weight loss plus 50%+ cholesterol reduction and cardiovascular benefit at competitive pricing.

Schleifer said core differentiation is the Praluent co-formulation, not competing on weight loss alone. Yancopoulos added the agent has already been studied extensively in China with tirzepatide-like efficacy/safety. Called the combo a 'Trojan horse' for cardiovascular disease prevention.

Schleifer defended regulatory team emphatically, no shortage of expertise or relationships. Attributed issues to fill/finish manufacturing dependency on third parties. Own fill/finish plant expected online next year. Noted even the biggest companies face same filler issues but don't disclose their CRLs.

Schleifer highlighted the complexity that Regeneron does not control OUS pricing for EYLEA (controlled by Bayer), and said new contracts will need to address the MFN contingency for licensed products. Acknowledged this as a real wrinkle that needs to be figured out.

Schleifer advocated for executive action to allow direct manufacturer copay assistance for Medicare patients, arguing current system forces poor patients onto inferior treatments like Avastin.